RG
IMCR icon

Rathbones Group’s Immunocore IMCR Stock Holding History

Rathbones Group’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-190,015
Closed -$8.92M – 429
2022
Q3 		$8.92M Hold
190,015
– – 0.11% 121
2022
Q2 		$7.09M Hold
190,015
– – 0.08% 136
2022
Q1 		$5.68M Hold
190,015
– – 0.06% 152
2021
Q4 		$6.51M Buy
+190,015
New +$6.88M 0.06% 148

Other funds holding IMCR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Rathbones Group's IMCR Position: Q4 2022 in Review

Rathbones Group sold out of Immunocore (IMCR) in Q4 2022, closing a stake of 190,015 shares — an estimated $8.92M sold.

Rathbones Group first reported a position in IMCR in Q4 2021 and held it in 4 quarters. The position peaked at $8.92M in Q3 2022. 104 funds tracked by Wall St. Rank hold IMCR as of Q4 2022.

  • Rathbones Group reported no remaining Immunocore position as of Q4 2022 after selling out during the quarter.
  • Rathbones Group sold 190,015 Immunocore shares in Q4 2022, an estimated $8.92M.
  • Rathbones Group first reported a position in Immunocore in Q4 2021 and held it in 4 quarters.
  • Rathbones Group's Immunocore position peaked at $8.92M in Q3 2022.
  • 104 funds tracked by Wall St. Rank held Immunocore as of Q4 2022.

Based on Rathbones Group's 13F filing for Q4 2022, filed 14 Feb 2023.